Xenon Pharmaceuticals Inc. 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 11, 2016
Insider Transaction Report
Form 4
GOLDBERG Y. PAUL
VP of Clinical Development
Transactions
- Award
Stock Option (Right to Buy)
2016-03-11+20,000→ 20,000 totalExercise: $7.49Exp: 2026-03-10→ Common Shares (20,000 underlying)
Footnotes (1)
- [F1]Vesting 25% on January 1, 2017, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.